August 2012
-
According to news reports, a Florida man lost his teeth and part of his tongue when the battery in an e-cigarette exploded in his mouth on February 14. The explosion also started a fire in… Read more . . .
-
A jury has awarded $18 million to Sunovion Pharmaceuticals after finding that Mylan willfully infringed on patents for Xopenex levalbuterol hydrochloride inhalation solution when its subsidiary Dey marketed generic versions of the product. The trial… Read more . . .
-
A Dallas, TX company called Wholistic Herbs Inc. has recalled all of the nasal spray products it distributed from March 2009 through February 2012 under the name “Koff & Kold” and “Kold Sore” after an… Read more . . .
-
Alexza Pharmaceuticals says that the Day 80 Assessment Report it has received from the European Medicines Agency (EMA) regarding its Marketing Authorization Application (MAA) for Adasuve Staccato loxapine indicates that the report “outlines major objections… Read more . . .
-
Finnish pharmaceutical company Orion Corporation has announced its intention to continue development of a generic budesonide/formoterol DPI despite the fact that “equivalence with the reference product, which is required under the guideline of the European… Read more . . .
-
Aptuit is a worldwide Contract Research Organization, collaborating with all the major Pharma and Biotech companies in support of various drug discovery and development projects. To efficiently support on going activities and needs, we are… Read more . . .
-
Insmed Incorporated has announced that it will go ahead with two clinical trials of its Arikace liposomal amikacin for inhalation for non-tuberculous mycobacteria (NTM) lung disease and for P. aeruginosa infections in CF patients despite… Read more . . .
-
Update 3/7/2012: The FDA issues a warning letter on inhalable caffeine. Update 2/19/2012: The FDA says it will review the safety and legality of AeroShot inhaled caffeine. In 2008, Harvard professor David Edwards gave a… Read more . . .
-
A new report from IbisWorld foresees a positive outlook for nebulizer sales after estimated annualized growth rate of 6.2% from 2007 to 2012. The report suggests that an aging population and increasing diagnoses of respiratory… Read more . . .
-
As GSK announced its 2011 results, which included sales declines for Advair (Seretide) in the US and Europe, and after the announcement that it plans to file a marketing application for its Relovair fluticasone furoate/vilanterol… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland